Crossmark

2242 Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis

Crossref DOI link: https://doi.org/10.1136/bmjno-2022-ANZAN.26

Published Online: 2024-02-01

Published Print: 2022-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Roos, Izanne

Sharmin, Sifat

Lechner-Scott, Jeannette

Buzzard, Katherine

Skibina, Olga

Walt, Anneke van der

Butzkueven, Helmut

Butler, Ernest

MacDonell, Richard

McCombe, Pamela

Slee, Mark

Malpas, Charles

Kalincik, Tomas